Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 2/20 | 0.51 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | FAAH | O00519 | 2/20 | 0.41 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
| ▸ | MGLL | Q99685 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5113084 | 0.82 | LTA4H (0.53) | LTA4HPTGS2NPC1MAPTHTT | |
| SCHEMBL27632627 | 0.80 | FAAH (0.55) | LTA4HPTGS2FAAHMGLL | |
| SCHEMBL5106952 | 0.76 | ALDH1A1 (0.60) | NPC1MAPTHTTRAB9AFAAH | |
| SCHEMBL27613685 | 0.76 | LTA4H (0.45) | LTA4HPTGS2NPC1MAPTHTT | |
| SCHEMBL4481635 | 0.74 | SIGMAR1 (0.65) | DRD4SIGMAR1 | |
| SCHEMBL5024073 | 0.73 | PTGS2 (0.50) | LTA4HPTGS2NPC1MAPTRAB9A | |
| SCHEMBL646795 | 0.73 | LTA4H (0.50) | LTA4HPTGS2NPC1CHRM5HRH3 | |
| SCHEMBL14577578 | 0.72 | CHRM5 (0.59) | LTA4HPTGS2CHRM5 | |
| SCHEMBL11143982 | 0.72 | PTGS2 (0.57) | LTA4HPTGS2NPC1RAB9AHRH3 | |
| SCHEMBL19206080 | 0.71 | LTA4H (0.56) | LTA4HPTGS2HTTFAAHMGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7365082-B2 | N-(substituted arylmethyl)-4-(disubstituted methyl)piperidines and piperazines | BAYER CROPSCIENCE AG (DE) | 2008-04-29 | — | — | US | disclosed |
| US-20060166962-A1 | N-(substituted arylmethyl)-4-(disubstituted methyl)piperidines and piperazines | FMC CORPORATION | 2006-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060166962-A1 | N-(substituted arylmethyl)-4-(disubstituted methyl)piperidines and piperazines | DDT, DRD4, DRD1 | LTA4H 2810/4885PTGS2 3613/4885NPC1 972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.